IGF2BP2 and hepatocellular carcinoma: For IGF2BP2, its splice variant p62 has been shown to influence chemoresistance due to antiapoptotic actions [15] and a more aggressive tumor phenotype [16] in hepatocellular carcinoma (HCC).